Molecular Weight(MW): 363.84
Naloxone HCl is an opioid inverse agonist drug used to counter the effects of opiate overdose.
Purity & Quality Control
Choose Selective Opioid Receptor Inhibitors
|Description||Naloxone HCl is an opioid inverse agonist drug used to counter the effects of opiate overdose.|
Naloxone significantly reduces the LPS-induced degeneration of the midbrain neurons. Naloxone inactives stereoisomer (+)-naloxone protected the dopaminergic neurons with equal potency. Naloxone inhibits LPS-induced activation of microglia and release of proinflammatory factors, and inhibition of microglia generation of superoxide free radical best correlated with the neuroprotective effect of naloxone isomers. Naloxone is found to partially inhibit the binding of [(3)H]LPS to cell membranes, whereas it failes to prevent damage to dopaminergic neurons by peroxynitrite, a product of nitric oxide and superoxide.  Naloxone (18.0 mg/kg) suppresses water intake when water is presented as the sole source of fluid. Naloxone produces a dose-dependent decrease in ethanol consumption, without altering water intake, when rats are given a free-choice between the ethanol solution and water. 
|In vivo||Naloxone (10 mg/kg) causes a dose-dependent reduction of break-points and locomotor activity in both the beer and near-beer rats.  Naloxone inhibits the LPS-induced activation of microglia and significantly reduces the LPS-induced loss of dopaminergic neurons in the rat substantia nigral.  Naloxone abolishes this antinociceptive activity both in the hot-plate test and in the first phase of the formalin test without affecting the serum concentration of paracetamol. Naloxone prevents the increase in 5-HT concentration in the central nervous system and the reduction in 5-HT2 receptors in cortical membranes. |
|In vitro||DMSO||72 mg/mL (197.88 mM)|
|Water||72 mg/mL (197.88 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT02922959||Active not recruiting||Drug Overdose|Opioid-Related Disorders|Drug Addiction|Drug Abuse|Substance Abuse||University of Cincinnati|National Institute on Drug Abuse (NIDA)||February 7 2017||Not Applicable|
|NCT03266445||Not yet recruiting||Opioid-use Disorder|Pain Acute|Surgery||Massachusetts General Hospital||October 5 2018||Phase 4|
|NCT03687268||Recruiting||Opioid-Induced Constipation||Develco Pharma Schweiz AG||July 31 2017||Phase 3|
|NCT03386591||Completed||Opioid-use Disorder||National Institute on Drug Abuse (NIDA)||January 3 2018||Phase 1|
|NCT02032433||Completed||Opioid Use Disorder||New York University School of Medicine|National Institute on Drug Abuse (NIDA)|The EMMES Corporation||January 29 2014||Phase 4|
|NCT03248947||Recruiting||Opioid Use Disorder||Duke University|National Institute on Drug Abuse (NIDA)|The EMMES Corporation||March 28 2018||Early Phase 1|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.